Open Access

ARTICLE

Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer

Shuai Liu^*†1, Lu Lu^*†1, Feng Pan^‡, Chunsheng Yang^*†, Jing Liang^§, Jinfeng Liu^¶, Jian Wang^#, Rong Shen^**, Fu-Ze Xin^††, Nan Zhang^*†

* Department of Breast Disease Diagnosis and Treatment Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, P.R. China
† Department of Breast Disease Diagnosis and Treatment Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, P.R. China
‡ Ethics Committee Office, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, P.R. China
§ Department of Oncology, Shandong Provincial Qianfoshan Hospital, Jinan, P.R. China
¶ Department of Oncology, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, P.R. China
# Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, P.R. China
** Department of Chemotherapy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, P.R. China
†† Department of Gastrointestinal Surgery, Liao Cheng People’s Hospital, Liaocheng, P.R. China

Oncology Research 2021, 29(1), 25-31. https://doi.org/10.3727/096504022X16427607626672

Abstract

Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival (PFS) was evaluated using the Kaplan–Meier method. The efficacy and safety of fruquintinib were also assessed. Seventy-five patients were involved in our study, and 29.3% of patients achieved stable disease (SD). Median PFS was 5.4 months (95% CI: 4.841–5.959). The treatment-emergent adverse events (TEAEs) with fruquintinib were acceptable with grade 3 TEAEs of 6%. The grade 3 TEAEs were hand–foot skin reaction (HFSR), fatigue, and stomatitis. The ECOG performance status was associated with PFS. In this real-world study, the clinical activity of fruquintinib was consistent with what has been reported in previous clinical trials. The level of safety was acceptable, and the side effects were manageable.

---

Keywords

---